FindTrial
Sign In

Clinical Randomized Controlled Trial of Artificial Intelligence-Optimized Acupoint Selection for Intervention in Post-Stroke Cognitive Impairment and Machine Learning-Based Prediction of MRI Biomarkers

Clinical Randomized Controlled Trial on Artificial Intelligence-Optimized Acupoint Selection - Head-Well Interaction Method for Intervention in Post-Stroke Cognitive Impairment and Machine Learning-Based Prediction of MRI Biomarkers

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001604
Enrollment
Unknown
Registered
2025-08-25
Start date
2025-08-12
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-stroke cognitive impairment

Interventions

Intervention Group:Head-Well Interaction Acupuncture
Control group:General Acupuncture

Sponsors

First teaching hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Stroke patients meeting the diagnostic criteria established by the Fourth National Cerebrovascular Diseases Academic Conference (1995), with hemorrhagic/ischemic stroke confirmed by cranial CT or MRI; and meeting the diagnostic criteria for Post-Stroke Cognitive Impairment (PSCI) per the 2021 Expert Consensus on PSCI Management. (2) First-ever stroke with disease duration =14 days. (3) Identified as high-risk for PSCI (Montreal Cognitive Assessment, MoCA <26) and scoring =7 on the NINDS-CSN 5-minute protocol. (4) Age 35–75 years, regardless of gender. (5) Absence of severe aphasia allowing completion of cognitive tests. (6) Stable vital signs without progression of neurological symptoms. (7) No pre-stroke diagnosis of cognitive impairment-related disorders. (8) Provision of written informed consent.

Exclusion criteria

Exclusion criteria: (1) Failure to meet the inclusion criteria. (2) Complete left prefrontal cortex injury confirmed by CT/MRI. (3) Severe functional failure of vital organs (e.g., heart, brain, kidneys). (4) History of cranial surgery or skull defects. (5) Metallic implants or cardiac pacemakers (MRI contraindications). (6) Neuropsychiatric comorbidities or affective disorders that may compromise test validity. (7) Unstable vital signs, hematological diseases, autoimmune disorders (e.g., rheumatism), or malignancy. (8) Any other factors potentially interfering with cognitive assessment or treatment.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment (MoCA);Mini-Mental State Examination (MMSE);Incidence of Post-Stroke Cognitive Impairment;—

Secondary

MeasureTime frame
National Institutes of Health Stroke Scale (NIHSS);Modified Barthel Index (MBI);—

Countries

China

Contacts

Public ContactBo Li

First teaching hospital of Tianjin University of Traditional Chinese Medicine

ibou119@163.com13323332911

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026